Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Fulcrum Therapeutics (FULC) over the last 6 years, with Sep 2025 value amounting to $64,000.

  • Fulcrum Therapeutics' Cash from Financing Activities fell 89.92% to $64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 63.29%. This contributed to the annual value of $2.7 million for FY2024, which is 97.68% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Cash from Financing Activities of $64,000 as of Q3 2025, which was down 78.74% from $301,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Cash from Financing Activities registered a high of $137.9 million during Q3 2021, and its lowest value of $64,000 during Q3 2025.
  • Its 3-year average for Cash from Financing Activities is $13.5 million, with a median of $301,000 in 2025.
  • Data for Fulcrum Therapeutics' Cash from Financing Activities shows a peak YoY increase of 166,248.19% (in 2021) and a maximum YoY decrease of 99.68% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Cash from Financing Activities stood at $891,000 in 2021, then slumped by 75.53% to $218,000 in 2022, then spiked by 31.65% to $287,000 in 2023, then crashed by 71.08% to $83,000 in 2024, then tumbled by 89.92% to $64,000 in 2025.
  • Its Cash from Financing Activities was $64,000 in Q3 2025, compared to $301,000 in Q2 2025 and $83,000 in Q4 2024.